Division
HEAL Study
Investigator(s)
Title
Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment (ACCENT)
Short Description
The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50).
Release Date
Jul 13, 2018
Description

The primary objective of this Phase 3 study is to evaluate the impact of N-Acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50). The primary outcome measure will be the odds of negative weekly urine cannabinoid tests during active treatment. Primary analysis will be based on an intent-to-treat evaluation of all participants randomized into the study, with missing urine specimens coded as missing and assumed to be positive. Sensitivity analyses will be performed to determine how other procedures for missing data affect results.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links
Division
HEAL Study
Investigator(s)
Title
Assessment of Interactions Between Methamphetamine and Aripiprazole
Short Description
The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.
Release Date
May 07, 2018
Description

This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links
Division
HEAL Study
Investigator(s)
Title
Assessment of Potential Interactions Between Methamphetamine and Bupropion
Short Description
The purpose of this study is to assess potential interactions between intravenous (IV) methamphetamine and oral bupropion.
Release Date
May 07, 2018
Description

This is a human laboratory clinical pharmacology study to assess potential interactions between IV methamphetamine challenge and treatment with oral sustained-release bupropion.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links

Wechsler Adult Intelligence Scale Digit Symbol subtest

Abbreviation
WAIS-Digit
Description

The WAIS-R consists of six verbal subtests and five performance subtests. The verbal tests are: Information, Comprehension, Arithmetic, Digit Span, Similarities, and Vocabulary. The Performance subtests are: Picture Arrangement, Picture Completion, Block Design, Object Assembly, and Digit Symbol.

Category
Impulsivity and General Trait & Behavior Scales
Division
HEAL Study
Investigator(s)
Title
Phase 2, Double-Blind Placebo-Controlled Trial Of Bupropion for the Treatment of Methamphetamine Dependence
Short Description
The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence.
Release Date
May 07, 2018
Description

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links

Positive and Negative Affect Schedule

Abbreviation
PANAS
Description

The Positive and Negative Affect Schedule (PANAS) measures the two primary dimensions of mood: Positive affect reflects the extent to which a person feels enthusiastic, active, and alert; negative affect is a general dimension of subjective distress and unpleasurable engagement that subsumes a variety of aversive mood states. The PANAS consists of 10 positive affects (interested, excited, strong, enthusiastic, proud, alert, inspired, determined, attentive, and active) and 10 negative affects (distressed, upset, guilty, scared, hostile, irritable, ashamed, nervous, jittery, and afraid). Participants are asked to rate items on a scale from 1 to 5, based on the strength of emotion where 1 = "very slightly or not at all," and 5 = "extremely."

Category
Mental Health
Subcategory
General/Multiple Disorders

Wisconsin Smoking Withdrawal Scale

Abbreviation
WSWS
Description

This 28-item scale was developed to contain reliable subscales tapping the major symptom elements of the nicotine withdrawal syndrome. It uses seven internally consistent subscales: anger, anxiety, sadness, concentration, sleep, hunger, and craving. Respondents rate each statement on a scale ranging from 0 (strong disagree) to 4 (strongly agree). The WSWS is sensitive to smoking withdrawal and predictive of smoking cessation outcomes, and its brevity makes it useful in both the clinical and research context.

Category
Substance Use
Subcategory
Tobacco